Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijcha.2017.11.001 http://scihub22266oqcxt.onion/10.1016/j.ijcha.2017.11.001 C5684093!5684093!29159270     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Cardiol+Heart+Vasc 2017 ; 17 (ä): 33-6 Nephropedia Template TP {{tp|p=29159270|t=2017. The circular RNA MICRA for risk stratification after myocardial infarction? |pdf=|usr=}}{{29159270}} gab.com Text The circular RNA MICRA for risk stratification after myocardial infarction JO: Int J Cardiol Heart Vasc http://www.kidney.de/pget.php?&tw=1&pmid=29159270 #FOAvip Background: A significant proportion of patients develop heart failure (HF) after acute myocardial infarction (MI). Predicting this development with novel biomarkers would allow tailoring healthcare to each individual. We recently identified a circular RNA called MICRA which was associated with HF development after MI. Here, we tested whether MICRA was able to risk stratify MI patients. Methods: MICRA was assessed in whole blood samples collected at reperfusion in 472 patients with acute MI. Left ventricular ejection fraction (EF) was evaluated by echocardiography at 4 months. Multivariable analyses with ordinal regression were conducted to determine the ability of MICRA to classify patients into 3 EF groups: reduced EF (? 40%), mid-range EF (4149%) and preserved EF (? 50%). Results: Eighty seven patients (18%) had a reduced EF, 106 (22%) had a mid-range EF and 279 (59%) had a preserved EF at 4 months. MICRA classified patients into EF groups with an adjusted odds ratio [95% confidence interval] of 0.78 [0.64?0.95]. MICRA improved the predictive value of a multivariable clinical model as attested by a decrease of the Akaike Information Criteria (p = 0.012). Bootstrap internal validation confirmed the incremental prognostic value of MICRA. Conclusion: We report that the circRNA MICRA improves risk classification after MI, supporting the added value of this novel biomarker in future prognostication strategies. Twit Text FOAVip The circular RNA MICRA for risk stratification after myocardial infarction ????Int J Cardiol Heart Vasc http://www.kidney.de/pget.php?&tw=1&pmid=29159270 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29159270 #FOAvip English Wikipedia <ref>{{Cite pmid|29159270}}</ref> The circular RNA MICRA for risk stratification after myocardial infarction? #MMPMID29159270 Salgado-Somoza A; Zhang L; Vausort M; Devaux Y Int J Cardiol Heart Vasc 2017[Dec]; 17 (ä): 33-6 PMID29159270show ga Background: A significant proportion of patients develop heart failure (HF) after acute myocardial infarction (MI). Predicting this development with novel biomarkers would allow tailoring healthcare to each individual. We recently identified a circular RNA called MICRA which was associated with HF development after MI. Here, we tested whether MICRA was able to risk stratify MI patients. Methods: MICRA was assessed in whole blood samples collected at reperfusion in 472 patients with acute MI. Left ventricular ejection fraction (EF) was evaluated by echocardiography at 4 months. Multivariable analyses with ordinal regression were conducted to determine the ability of MICRA to classify patients into 3 EF groups: reduced EF (? 40%), mid-range EF (4149%) and preserved EF (? 50%). Results: Eighty seven patients (18%) had a reduced EF, 106 (22%) had a mid-range EF and 279 (59%) had a preserved EF at 4 months. MICRA classified patients into EF groups with an adjusted odds ratio [95% confidence interval] of 0.78 [0.64?0.95]. MICRA improved the predictive value of a multivariable clinical model as attested by a decrease of the Akaike Information Criteria (p = 0.012). Bootstrap internal validation confirmed the incremental prognostic value of MICRA. Conclusion: We report that the circRNA MICRA improves risk classification after MI, supporting the added value of this novel biomarker in future prognostication strategies. äThe circular RNA MICRA for risk stratification after myocardial infarc(epmc).pdf DeepDyve Pubget Overpricing